Vanda Pharmaceuticals (VNDA) Equity Average (2016 - 2025)
Historic Equity Average for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Q4 2025 value amounting to $396.6 million.
- Vanda Pharmaceuticals' Equity Average fell 2654.12% to $396.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $396.6 million, marking a year-over-year decrease of 2654.12%. This contributed to the annual value of $432.9 million for FY2025, which is 2009.53% down from last year.
- Vanda Pharmaceuticals' Equity Average amounted to $396.6 million in Q4 2025, which was down 2654.12% from $476.2 million recorded in Q3 2025.
- Vanda Pharmaceuticals' Equity Average's 5-year high stood at $544.5 million during Q1 2024, with a 5-year trough of $396.6 million in Q4 2025.
- For the 5-year period, Vanda Pharmaceuticals' Equity Average averaged around $509.2 million, with its median value being $516.8 million (2022).
- In the last 5 years, Vanda Pharmaceuticals' Equity Average soared by 1189.63% in 2021 and then plummeted by 2654.12% in 2025.
- Quarter analysis of 5 years shows Vanda Pharmaceuticals' Equity Average stood at $499.1 million in 2021, then grew by 4.47% to $521.4 million in 2022, then increased by 4.33% to $544.0 million in 2023, then decreased by 0.76% to $539.9 million in 2024, then fell by 26.54% to $396.6 million in 2025.
- Its Equity Average stands at $396.6 million for Q4 2025, versus $476.2 million for Q3 2025 and $498.9 million for Q2 2025.